AVEO’s Ph 3 Results Demonstrate Nivolumab/Tivozanib Combo Does Not Provide Benefits Over Tivozanib Alone in RCC

AVEO Oncology has revealed that its Phase 3 clinical trial (TiNivo-2) results demonstrate the addition of Opdivo® (nivolumab) to low dose Fotivda® (tivozanib) after prior immune checkpoint inhibitor (ICI) treatment is not superior to standard dose tivozanib alone, with the primary endpoint of the study not being met for this reason.  AVEO considers this supports the approved use of tivozanib as a safe and effective treatment option in relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.